MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 106 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,113,130 | -26.5% | 138,277 | -0.9% | 0.00% | -100.0% |
| Q2 2023 | $1,514,720 | +44.8% | 139,477 | +24.6% | 0.00% | – |
| Q1 2022 | $1,046,000 | -20.3% | 111,914 | +1.2% | 0.00% | – |
| Q4 2021 | $1,313,000 | -3.3% | 110,551 | -7.4% | 0.00% | – |
| Q3 2021 | $1,358,000 | +84.5% | 119,323 | -7.1% | 0.00% | – |
| Q2 2021 | $736,000 | -44.7% | 128,456 | +49.4% | 0.00% | – |
| Q1 2021 | $1,331,000 | +30.1% | 85,974 | +2.5% | 0.00% | – |
| Q4 2020 | $1,023,000 | -10.2% | 83,901 | -5.3% | 0.00% | – |
| Q3 2020 | $1,139,000 | – | 88,583 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |